Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

Latest News

Irish regulator investigates Facebook over exposed passwords

Apr 25, 2019

LONDON — Ireland's privacy regulator says it's investigating Facebook over the social media giant's recent revelation that it had left hundreds of millions of user passwords exposed. The Irish Data Protection Commission said Thursday that it opened a statutory inquiry this week into Facebook after the company notified it about the security lapse. The company said last month that it had inadvertently stored passwords for users of Facebook, Facebook Lite and Instagram in plain text, making it possible for employees to search them. Facebook said it is working with the commission on the inquiry. "There is no evidence that these...

UK government says it hasn't decided yet on Huawei 5G role

Apr 25, 2019

LONDON — The British government has not yet decided whether to allow China's Huawei to supply parts for the U.K.'s new 5G wireless network, Digital Secretary Jeremy Wright said Thursday, as he condemned leaks from private government discussions on the sensitive issue. Wright said government officials and U.K. intelligence agencies are still carrying out a review on how best to strike the "difficult balance between security and prosperity." He told lawmakers in the House of Commons that "there has not been a final decision made on this subject." The United States has been lobbying allies to exclude Huawei from all...

Climate activists block entrance to London Stock Exchange

Apr 25, 2019

LONDON — Environmental activists who have brought disruption to the British capital for more than a week blocked the main entrance to the London Stock Exchange on Thursday, gluing themselves to the doorway while wearing LED displays reading "climate emergency." Several demonstrators also climbed atop a train at Canary Wharf station in east London's business district as they focused on the city's financial centers during a final day of protests in the capital. The group Extinction Rebellion said it was targeting the financial services industry for "funding climate and ecological destruction." Activists held signs saying "business as usual = death"...

UN: No screen time for babies; only 1 hour for kids under 5

Apr 25, 2019

LONDON — The World Health Organization has issued its first-ever guidance for how much screen time children under 5 should get: not very much, and none at all for those under 1. The U.N. health agency said Wednesday that kids under 5 should not spend more than one hour watching screens every day — and that less is better. The guidelines are somewhat similar to advice from the American Academy of Pediatrics. That group recommends children younger than 18 months should avoid screens other than video chats. It says parents of young children under two should choose "high-quality programming" with...

London climate protesters say they will end their blockades

Apr 25, 2019

LONDON — Climate change protesters who have brought parts of central London to a standstill for days say they will lift their blockades. The group Extinction Rebellion says it will end its remaining demonstrations at Marble Arch and Parliament Square on Thursday. Last week, the protesters blocked Waterloo Bridge and major intersections including Marble Arch and Oxford Circus, snarling traffic and disrupting bus routes. The civil disobedience movement saw tented protest sites sprouting around the capital. More than 1,000 people were arrested as police tried to clear the sites, though only about 70 have been charged. Extinction Rebellion thanked Londoners...

Sign up now!